questionText: To ask the Secretary of State for Health and Social Care, whether he plans to review the National Institute for Health and Care Excellence's decision not to recommend Ruxolitinib for use within NHS England for the treatment of vitiligo.
answerText: The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on whether ruxolitinib should be routinely funded by the NHS, based on an assessment of its costs and benefits.The NICE was unfor...
heading: Vitiligo: Ruxolitinib